The steep road to nonviral nanomedicines: Frequent challenges and culprits in designing nanoparticles for gene therapy

• Yao Yao,
• Yeongun Ko,
• Grant Grasman,
• Jeffery E. Raymond and
• Joerg Lahann

Beilstein J. Nanotechnol. 2023, 14, 351–361, doi:10.3762/bjnano.14.30

• polymeric (e.g., core–shell micelles), oligomeric (e.g., lipid nanoparticles), or biomacromolecular (e.g., protein nanoparticles) components complicates matters only further by generating a higher-than-normal background through non-specific interactions with the assay media. In addition, a significant bias

Systematic studies into uniform synthetic protein nanoparticles

• Nahal Habibi,
• Ava Mauser,
• Jeffery E. Raymond and
• Joerg Lahann

Beilstein J. Nanotechnol. 2022, 13, 274–283, doi:10.3762/bjnano.13.22

• , or monodispersity. Electrohydrodynamic (EHD) jetting is a probate method to formulate synthetic protein nanoparticles (SPNPs), but a systematic understanding of the influence of crucial processing parameters, such as protein composition, on nanoparticle morphologies is still missing. Here, we address

• as poorly defined physical properties and/or stability in the bloodstream [14]. Desolvation methods have been used to prepare various therapeutic protein nanoparticles [15][16][17]. The desolvation process requires the addition of desolvating agents, such as ethanol or acetone, to induce changes in

• protein structure (sometimes fully denaturing the protein) and to cause subsequent precipitation of protein aggregates [18]. Self-assembly strategies also provide access to a variety of structurally diverse [19] protein nanoparticles. With the advent of in silico design and subsequent production of de

Electrokinetic characterization of synthetic protein nanoparticles

• Daniel F. Quevedo,
• Cody J. Lentz,
• Adriana Coll de Peña,
• Yazmin Hernandez,
• Nahal Habibi,
• Rikako Miki,
• Joerg Lahann and
• Blanca H. Lapizco-Encinas

Beilstein J. Nanotechnol. 2020, 11, 1556–1567, doi:10.3762/bjnano.11.138

• treatment of a wide variety of diseases. However, the slow progress in the field has resulted in relatively few therapies being translated into the clinic. Anisotropic synthetic protein nanoparticles (ASPNPs) show potential as a next-generation drug-delivery technology, due to their biocompatibility

• ; bicompartmental particles; dielectrophoresis; electrokinetics; electrophoresis; electro-osmosis; microfluidics; protein nanoparticles; Introduction Over the past 30 years, nanoparticles have been developed for a wide variety of scientific applications, ranging from medical imaging to drug delivery and enzyme

• , naturally involved in biological molecule targeting, and are “smart” materials that can respond to various environmental cues, such as pH value, temperature, or target binding [4]. Protein nanoparticles (PNPs) are useful for the loading of active therapeutic enzymes and show potential results to be used as

Nanoencapsulation of ultra-small superparamagnetic particles of iron oxide into human serum albumin nanoparticles

• Matthias G. Wacker,
• Mahmut Altinok,
• Stephan Urfels and
• Johann Bauer

Beilstein J. Nanotechnol. 2014, 5, 2259–2266, doi:10.3762/bjnano.5.235

• ethanol at a rate of 1.5 mL/min under permanent stirring (550 rpm). Afterwards, a volume of aqueous glutaraldehyde solution 8% [v/v] corresponding to between 100% and 600% of stoichiometric crosslinking of the amino groups in 50 mg HSA was added to stabilize the resulting protein nanoparticles. Particles